Miriam Nickel1, Alessandro Simonati2, David Jacoby3, Susanne Lezius4, Dirk Kilian1, Benjamin Van de Graaf5, Odelya E Pagovich5, Barry Kosofsky5, Kaleb Yohay6, Matthew Downs7, Peter Slasor3, Temitayo Ajayi3, Ronald G Crystal5, Alfried Kohlschütter1, Dolan Sondhi5, Angela Schulz8. 1. Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Neuroscience, Biomedicine, Movement-Neurology (Child Neurology and Psychiatry, and Neuropathology), University of Verona, Verona, Italy. 3. BioMarin Pharmaceutical, Novato, CA, USA. 4. Department of Biometrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA. 6. Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA; Department of Neurology, New York University, Langone Medical Center, New York, NY, USA. 7. Statistics Collaborative, Washington, DC, USA. 8. Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: anschulz@uke.de.
Abstract
BACKGROUND: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients. METHODS: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression-measured by the rate of decline in motor and language summary scores (on a scale of 0-6 points)-and time from first symptom to death. FINDINGS: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0-38·5) at first clinical symptom, 37·0 months (IQR 35·0 -42·0) at first seizure, and 54·0 months (IQR 47·5-60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70%]), language difficulty (42 [57%]), motor difficulty (30 [41%]), behavioural abnormality (12 [16%]), and dementia (seven [9%]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95% CI 1·50-2·12) was seen in motor-language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years. INTERPRETATION: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies. FUNDING: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.
BACKGROUND:Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients. METHODS: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression-measured by the rate of decline in motor and language summary scores (on a scale of 0-6 points)-and time from first symptom to death. FINDINGS: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0-38·5) at first clinical symptom, 37·0 months (IQR 35·0 -42·0) at first seizure, and 54·0 months (IQR 47·5-60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70%]), language difficulty (42 [57%]), motor difficulty (30 [41%]), behavioural abnormality (12 [16%]), and dementia (seven [9%]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95% CI 1·50-2·12) was seen in motor-language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years. INTERPRETATION: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies. FUNDING: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.
Authors: Angela Schulz; Simon Dulz; Yevgeniya Atiskova; Jan Wildner; Eva Wibbeler; Miriam Nickel; Martin Stephan Spitzer; Christoph Schwering Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-06-02 Impact factor: 3.535
Authors: Kyle D Kovacs; Samir Patel; Anton Orlin; Keunpyo Kim; Sherri Van Everen; Therese Conner; Dolan Sondhi; Stephen M Kaminsky; Donald J D'Amico; Ronald G Crystal; Szilárd Kiss Journal: Ophthalmol Retina Date: 2020-01-22
Authors: Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer Journal: Nat Rev Neurol Date: 2019-03 Impact factor: 42.937
Authors: Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi Journal: Expert Opin Orphan Drugs Date: 2019-11-27 Impact factor: 0.694
Authors: Dolan Sondhi; Stephen M Kaminsky; Neil R Hackett; Odelya E Pagovich; Jonathan B Rosenberg; Bishnu P De; Alvin Chen; Benjamin Van de Graaf; Jason G Mezey; Grace W Mammen; Denesy Mancenido; Fang Xu; Barry Kosofsky; Kaleb Yohay; Stefan Worgall; Robert J Kaner; Mark Souwedaine; Bruce M Greenwald; Michael Kaplitt; Jonathan P Dyke; Douglas J Ballon; Linda A Heier; Szilard Kiss; Ronald G Crystal Journal: Sci Transl Med Date: 2020-12-02 Impact factor: 17.956
Authors: J Schaefers; L J van der Giessen; C Klees; E H Jacobs; S Sieverdink; M H G Dremmen; J K H Spoor; A T van der Ploeg; J M P van den Hout; H H Huidekoper Journal: Orphanet J Rare Dis Date: 2021-05-14 Impact factor: 4.123
Authors: Christoph Schwering; Gertrud Kammler; Eva Wibbeler; Martin Christner; Johannes K-M Knobloch; Miriam Nickel; Jonas Denecke; Michael Baehr; Angela Schulz Journal: J Child Neurol Date: 2021-02-05 Impact factor: 1.987
Authors: Alexandra M Johnson; Simone Mandelstam; Ian Andrews; Katja Boysen; Joy Yaplito-Lee; Michael Fietz; Lakshmi Nagarajan; Victoria Rodriguez-Casero; Monique M Ryan; Nicholas Smith; Ingrid E Scheffer; Carolyn Ellaway Journal: J Paediatr Child Health Date: 2020-04-24 Impact factor: 1.954